DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF AMF REGULATED INFORMATIONMontrouge, France, January 21, 2022 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF. As of December 31, 2021, the following assets appeared on the liquidity account: 153,631 DBV Technologies shares;€ 175,542.33. Upon signing the liquidity contract in July 2018, the ...
Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF Informations Réglementées Montrouge, France, le 21 janvier (22 h 30 CET) 2022 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), société biopharmaceutique française, publie aujourd’hui le bilan semestriel de son contrat de liquidité avec ODDO BHF. A la date du 31 décembre 2021, les moyens suivants figuraient au compte de liquidité : 153 631 titres DBV Technologies ;175 542,33 euros. Lors de la mise en ...
The independent financial analyst theScreener just lowered the general evaluation of DBV TECHNOLOGIES (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 1 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Negative. As of the analysis date January 14, 2022, the closing price was EUR 2.98 and its target price was estimated at EUR 2.59.
Q4 sales beat CS expectations by 1% Anticipated normalizing trends in Q4 Robust US trends, terminated licences and Covid weighed on performances of Europe and Asia-Pacific FY21 margin outlook slightly better than expected What to expect for 2022?
Significant margin beat in Q4 Q4 FX-n growth was also better-than-expected Inventories start again a healthy reduction Current trading in line with CS expectations FY21 divided of SEK6.5 and new share buyback programme announced
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.